MedTrace Logo

A Prospective Real World Study of Rimegepant in the Treatment of Migraine

NCT05709106 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 173

Last updated 2026-02-05

No results posted yet for this study

Summary

The goal of this observational study is to test the effectiveness and safety of Rimegepant in the treatment of migraine patients in real world.

The main questions it aims to answer are:

* \[question 1\] the effectiveness and safety of Rimegepant in the acute treatment of migraine
* \[question 2\] the effectiveness and safety of Rimegepant in the long-term treatment of migraine.

1. Participants will be asked to take Rimegepant when they need to treat or prevent a migraine attack.
2. Participants will be asked to record the efficacy data at 0.5, 1, 2, 24, 48h post dose and report any AE to evaluate the effectiveness and safety of Rimegepant in the acute treatment of migraine
3. Participants will be asked to track monthly migraine days and the use of Rimegepant, finish 2 PROs during the follow-ups, report any AE to evaluate the effectiveness and safety of Rimegepant in the long-term treatment of migraine.

Conditions

Interventions

DRUG

Rimegepant 75 MG

Migraine patients would take Rimegepant 75 MG to treat or prevent a migraine attack and patients would be followed up for 1 year

Sponsors & Collaborators

  • Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine

    lead OTHER

Principal Investigators

  • Jun Liu · Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-11
Primary Completion
2024-10-06
Completion
2025-04-09
FDA Drug
Yes

Countries

  • China

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05709106 on ClinicalTrials.gov